The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) announced it is conducting final testing on a transdermal BPC-157 patch designed to deliver the peptide without injections.

The Vancouver-based company said the wearable patch is currently in active testing, with results expected in the near term. Subject to satisfactory completion of testing milestones, the company intends to progress the product toward commercial release.

The patch represents the company's attempt to address what it identifies as a barrier to peptide adoption. The company stated that research consistently shows needle aversion as a leading obstacle to therapies that consumers would otherwise consider.

"This is the product that brings peptides into the mainstream," said Pratap Sandhu, CEO of The Precision Peptide Company. "The needle has historically been the single biggest barrier to entry for this category, and removing it fundamentally changes who the customer is."

The transdermal delivery system eliminates the reconstitution, sterile handling, and dose measurement associated with injectable peptide therapies, according to the company.

Justin Kirkland, Chief Scientific Officer of Amino Innovations, noted that translating BPC-157 from an injectable into a transdermal format required formulation work to ensure consistent delivery through the skin.

The BPC-157 patch is the first product from the company's transdermal patch pipeline. A second patch containing Thymosin Alpha-1 is also under development and expected to follow BPC-157 through testing toward commercial readiness.

Patch development is supported by a research services agreement with the Drug Development and Innovation Centre at the University of Alberta, where faculty members provide expertise in absorption, bioavailability, and stability work.

The company cautioned that there is no assurance the current testing will produce satisfactory results or that the patches will be commercialized on contemplated timelines.